How to turn expiring blockbusters into budget wins — before your competitors do Patent cliffs don’t sneak up on anyone. […]

How hospital systems, PBMs, and self-insured employers can use IP intelligence to time generic switches and eliminate billions in avoidable

Darshan Kulkarni PharmD, MS, Esq. www.kulkarnilawfirm.com Introduction The intersection of intellectual property (IP) and artificial intelligence (AI) has triggered a

A complete guide for pharmaceutical executives, IP strategists, generic manufacturers, and investors navigating one of the world’s most distinctive patent

The UK Patent Box slashes the effective corporation tax rate on patented-drug profits from 25% to 10%. That 15-percentage-point gap

Generic drug companies do not compete on science. They compete on timing, legal nerve, and an encyclopedic understanding of a

The most sought-after scientists in biopharma rarely post their resumes to LinkedIn. They don’t have to. Their work announces them

When a European patent dies — formally, irrevocably, at the hands of the European Patent Office’s Technical Board of Appeal

When Johnson & Johnson’s multiple myeloma franchise Darzalex (daratumumab) generated roughly $10 billion in global revenue in 2024, it stood